Fact Source: Financial Supervisory Service DART / 2025-07-23
Disclosure Type: Preliminary Earnings Results based on Consolidated Financial Statements (Fair Disclosure)
💡 3-Second Summary
Samsung Biologics announced that its preliminary operating profit for the second quarter of 2025 reached approximately KRW 475.6 billion, up 9.46% year-over-year, while its cumulative first-half operating profit surged by 46.73% to KRW 962.3 billion.
📊 1. [Key Disclosure Content & Summary of Financial Figures]
- Company Name: Samsung Biologics Co., Ltd. (207940)
- Q2 2025 Quarterly Performance (Quarterly Comparison):
- Revenue: KRW 1,289,905 million (approx. KRW 1.29T) / Decreased by 0.64% compared to the previous quarter (Q1 2025), Increased by 11.50% compared to the same period last year (Q2 2024)
- Operating Profit: KRW 475,600 million (approx. KRW 475.6B) / Decreased by 2.28% compared to the previous quarter (Q1 2025), Increased by 9.46% compared to the same period last year (Q2 2024)
- Income before Income Taxes from Continuing Operations: KRW 408,905 million (approx. KRW 408.9B) / Decreased by 18.12% compared to the previous quarter, Decreased by 12.06% compared to the same period last year
- Net Income: KRW 324,386 million (approx. KRW 324.4B) / Decreased by 13.62% compared to the previous quarter, Increased by 2.01% compared to the same period last year
- H1 2025 Cumulative Performance (First-Half Comparison):
- Cumulative Revenue: KRW 2,588,178 million (approx. KRW 2.59T) / Increased by 23.02% compared to H1 2024
- Cumulative Operating Profit: KRW 962,288 million (approx. KRW 962.3B) / Increased by 46.73% compared to H1 2024
- Cumulative Net Income: KRW 699,940 million (approx. KRW 699.9B) / Increased by 40.73% compared to H1 2024
- Other Material Terms:
- These figures are preliminary results that have not been audited by an external auditor and may change pending the final audit. Detailed analytical files are scheduled to be published on the corporate website.
- The disclosure did not provide specific or detailed reasons for the fluctuations in financial performance.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This announcement serves as a preliminary consolidated earnings release, offering a clear snapshot of the company’s single-quarter performance and cumulative first-half growth quality. While sequential comparison with Q1 2025 shows a minor consolidation phase—with revenue slipping 0.64% and operating profit declining 2.28%—the year-over-year metric demonstrates solid top-line expansions, with revenue and operating profit scaling up by 11.50% and 9.46%, respectively.
The primary highlight for global investors lies within the cumulative metrics for H1 2025. Cumulative revenue reached approximately KRW 2.59T, climbing 23.02% compared to the first half of 2024, while cumulative operating profit marked a substantial 46.73% growth to settle at KRW 962.3 billion. Cumulative net income also advanced by 40.73%, illustrating enhanced bottom-line efficiency over the six-month span. However, investors may note that the quarterly pre-tax income from continuing operations dropped 12.06% year-over-year, and since the filing did not explain the underlying drivers for these fluctuations, tracking the detailed supplementary materials to be uploaded on the corporate IR page alongside the definitive audited results remains prudent.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics has just unleashed its Q2 2025 earnings card! While the sequential top and bottom lines took a tiny breather compared to Q1, the year-over-year engine remains fiercely intact. The ultimate takeaway for momentum hunters is the massive acceleration in the first-half cumulative numbers: cumulative operating profit skyrocketed by a staggering 46.73% to hit KRW 962.3 billion! Although the raw filing leaves out the explicit drivers behind this growth and remains subject to the final external audit, the cumulative growth trajectory is undeniable. Lock in these preliminary targets and monitor how they solidify into definitive audited results!
📢 Disclaimer & Source Information
Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
